Additionally, the heterogeneity of the Luminal B and HER2 molecular subtypes, especially intratumor heterogeneity, presents substantial challenges in cancer treatment; therefore, further studies are needed to identify more accurate molecular models for these patient subgroups. Here, ERBB2 is linked to cancer.